Endocrine Diseases and Pharmacogenomics
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 23 June 2025 | Viewed by 52
Special Issue Editors
Interests: RNA biology; regulatory RNA molecules; extracellular vesicles; identification of genetic defects in inherited diseases
Special Issues, Collections and Topics in MDPI journals
Interests: Inherited endocrine disorders; congenital adrenal hyperplasia; puberty; MODY; MEN2; DSD
Special Issues, Collections and Topics in MDPI journals
Interests: congenital adrenal hyperplasia; puberty; GnRH regulation; endocrine disorders; multiple endocrine neoplasia
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The integration of pharmacogenomics into the treatment of endocrine diseases, including Congenital Adrenal Hyperplasia (CAH), Maturity Onset Diabetes of the Young (MODY), Multiple Endocrine Neoplasia Type 2 (MEN2), Pseudohypoparathyroidism (PHP), Thyroid Hormone Resistance (THR), and others, shows significant potential to personalize treatment. This approach aims to optimize the use of clinically relevant drugs and enables personalized therapies for inherited endocrine disorders, improving efficacy and minimizing adverse effects. Despite promising research, much of this field's potential remains unexploited. Many pharmacogenetic findings need validation through large, well-designed clinical trials to confirm their relevance. The complexity of gene–drug interactions and diverse patient populations highlights the need for robust studies to turn discoveries into practical treatments. This Special Issue aims to explore any aspect of the search for endocrine treatments informed by pharmacogenomics. Contributions in the form of opinions, brief reports, communications, research articles, and reviews are welcomed.
Prof. Dr. Leonidas A. Phylactou
Dr. Vassos Neocleous
Dr. Pavlos Fanis
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- inherited endocrine disorders
- pharmacogenomics
- pharmacogenetics
- genome sequencing
- clinical trials
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
